Skip to main content

Table 1 Patient information and data involved in the study

From: CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy

Case Age Chemotherapy in Addition to Doxorubicin Pathologic TNM Stage Ki67 RCB Score RCB Class CREB3L1 IRS
1 40-49 Cytoxan, Taxol, Xeloda ypT2pN3M1 IV 84 4.186 3 1
2 50-59 Cytoxan, Xeloda, Taxol ypT2pN1M1 IV 45 4.387 3 0.5
3 50-59 Cytoxan, Taxol ypT1bN0M0 IA 90 1.340 1 0.5
4 30-39 Cytoxan, Taxol ypT2N3M0 IIIC 70 4.340 3 1
5 40-49 Cytoxan, Taxol ypT0N1miM0 IB 95 1.125 1 10
6 50-59 Halaven, Paraplatin, Taxol ypT2N1M1 IV 90 3.290 3 0.5
7 50-59 Cytoxan, Paraplatin, Taxol ypT1cN1M0 IIA 30 3.014 2 6
8 40-49 Cytoxan, Taxol ypT0N0M0 0 95 0 0 8
9 40-49 Cytoxan, Paraplatin, Taxol, Xeloda ypT2N1M1 IV 35 1.390 2 2
10 40-49 Cytoxan, Gemzar, Paraplatin, Taxol ypT1bN1M0 IIA 20 3.023 2 8
11 40-49 Cytoxan, Taxol ypT2N0M0 0 60 0 0 2
12a 50-59 Arimidex, Cytoxan, Paraplatin, Taxol ypT2N1M0 IIB 80 3.900 3 0
13 40-49 Cytoxan, Taxol, Xeloda ypT2N0M0 0 85 2.452 2 1
14 70-79 Cytoxan, Taxol ypT0N0M0 0 90 0 0 6
15 50-59 Cytoxan, Taxol ypT1miN0M0 0 95 1.322 1 6
16a 50-59 Arimidex, Cytoxan, Taxol ypT1cN0M0 IA 95 2.009 2 4
17a 40-49 Arimidex, Cytoxan, Taxol ypT1cN0M0 IA 70 2.140 2 1
18a 60-69 Arimidex, Cytoxan, Taxol ypTisN0M0 0 80 0 0 8
  1. All patients were diagnosed and treated between 2011 and 2017 at UT Southwestern University Hospitals. Patient age range and chemotherapeutic drugs in addition to doxorubicin used in the treatment are shown. Response of the tumors to the chemotherapy measured through RCB Scores and RCB Classes, CREB3L1 expression in the tumors measured by IRS values, percentage of tumor cells positively stained by anti-Ki67, and other clinical characterization of the tumors is also presented
  2. aThese patients had two different breast cancers: one breast with TNBC; the other with ER positive cancer. Only TNBC but not the ER-positive tumors were analyzed in this study